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Abstract
Glioblastoma multiforme (GBM) is associated with high mortality due to infiltrative growth
and recurrence. Median survival of the patients is less than 15 months, increasing require-
ments for new therapies. We found that both arsenic trioxide and 10058F4, an inhibitor of
Myc, induced differentiation of cancer stem-like cells (CSC) of GBM and that arsenic trioxide
drastically enhanced the anti-proliferative effect of 10058F4 but not apoptotic effects.
EGFR-driven genetically engineered GBMmouse model showed that this cooperative ef-
fect is higher in EGFRvIII-expressing INK4a/Arf-/- neural stem cells (NSCs) than in control
wild type NSCs. In addition, treatment of GBM CSC xenografts with arsenic trioxide and
10058F4 resulted in significant decrease in tumor growth and increased differentiation with
concomitant decrease of proneural and mesenchymal GBM CSCs in vivo. Our study was
the first to evaluate arsenic trioxide and 10058F4 interaction in GBM CSC differentiation
and to assess new opportunities for arsenic trioxide and 10058F4 combination as a promis-
ing approach for future differentiation therapy of GBM.
Introduction
Glioblastoma multiforme (GBM) is one of the most common malignant primary brain tumors
in adult and highly resistant to conventional chemotherapy[1,2]. Constitutive-active mutation
of EGFR (EGFRvIII) and loss of CDKN2a (INK4a/Arf) are often observed in GBM[3–7]. Con-
stitutive EGFR activation is sufficient to transform INK4a/Arf-deficient neural stem cells
(NSCs) and astrocytes into cancer stem-like cells (CSCs), which has high tumorigenicity in
vivo[8]. GBM CSCs are considered to be an origin of tumor and recurrence [9] and are an im-
portant therapeutic target. CSCs can be cultured in serum-free medium supplemented with
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bFGF and EGF in sphere conditions [10]. When transplanted to immunodeficient mice, CSCs
gave rise to high-grade gliomas with pathological phenotypes more similar to GBM compared
with GBM cells cultured in serum-containing media [10].
Arsenic trioxide (As2O3) is used for treatment of acute promyelocytic leukemia (APL),
which causes the induction of differentiation of leukemic cells [11,12]. Arsenic trioxide has
been reported to inhibit but not regress the growth of a wide variety of solid tumors including
GBM at a clinically safety dose (1–2μM). Higher concentrations (10–50μM) are required to in-
duce apoptosis [13–18]. 4μM arsenic trioxide reduces the number of CSCs of GBM, whereas
the low concentrations of arsenic trioxide only inhibits renewal of CSCs without affecting
properties as CSCs[18]. Thus, new method to enhance its efficacy requires to be exploited. An-
other candidate target of GBM therapy is c-Myc, which is also required for the maintenance of
CSC of various cancers [19]. We show here that a low concentration (2μM) of arsenic trioxide
could induce differentiation of GBM CSCs and enhanced the effect of 10058F4, a Myc inhibi-
tor. This interation was grater in EGFRvIII-expressing INK4a/Arf-deficient neural stem cells
(NSCs) than in wild type NSCs, which suggests a possibility of the application of this combina-
tion effect to a therapy of GBM.
Materials and Methods
Primary tumor cultures
Primary GBM surgical specimens were obtained from patients undergoing surgical treatment
for newly diagnosed GBM at Shiga Medical Center. This study was approved by the Ethical
Committee of the Human Research of Shiga Medical Center. The details of the study were ex-
plained to patients before they underwent surgery at Shiga Medical Center. Written agreement
had been obtained from a patient for the use of the resected tissue for this research, and de-
identified tissues were subjected to the analyses in this study. Within 1 h after surgical removal,
tumors were washed and enzymatically dissociated into single cells using a neural cell dissocia-
tion kit containing papain (Miltenyi Biotec). CSC sphere cells were cultured in NeuroCult NSC
Basal Medium (StemCell Technologies, Vancouver, BC, Canada) containing NeuroCult NSC
proliferation Supplements (StemCell Technologies), recombinant bFGF and EGF (40 ng/ml
each; Peprotech). RI01 and RI02 lines were derived from a 67-year-old man and a 72-year-old
man with glioblastoma multiforme, respectively. RI03 and RI08 lines originated from a 77-year
old woman, and 57-year-old woman with glioblastoma multiforme, respectively.
Primary CSC neurospheres were dissociated every 4 to 7 days to facilitate cell growth. To
promote differentiation, CSC neurospheres were enzymatically dissociated, seeded on a
Matrigel-coated slide chamber (Nunc) cultured in the same medium without bFGF and EGF
but in the presence of 1% FCS for 1 or 3 days. All primary cells were used at low (<30)
passage number.
Neural stem cell cultures
Normal neural stem cells were isolated from the ganglionic eminences of E14.5 INK4/Arf-/-
and control embryos. Cells were cultured in NeuroCult NSC Basal Medium (StemCell Tech-
nologies, Vancouver, BC, Canada) containing Neurocult NSC proliferation Supplements
(StemCell Technologies), recombinant bFGF and EGF (40 ng/ml each; Peprotech). These cells
were subsequently infected with EGFRvIII expressing MSCV retrovirus at first passage and
treated with puromycin (0.25μg/ml) 48 h after infection. To promote differentiation, EGFR-
vIII-expressing INK4/Arf-/- neural stem cells were dissociated from neurospheres, seeded on a
Matrigel-coated slide chamber (Nunc) and cultured in the same medium without bFGF and
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EGF but in the presence of 1% FCS. Cells were then fixed with 4% PFA for 15 minutes and
processed for immunohistochemistry.
Reagents
10058-F4 (Sigma-Aldrich, St Louis, MO) was dissolved in dimethyl sulfoxide. Arsenic trioxide
(Sigma Chemical Co. St. Louis, MO) was dissolved in 5 M solution of sodium hydroxide and
then its pH was adjusted to 8.0 with hydrochloric acid. The prepared concentrated solutions
were added to the culture medium and mixed gently.
Cell viability and Caspase 3/7 assay
Cell viability and caspase3/7 activity were determined using PrestoBlue Cell Viability Reagent
and CellEvent Caspase-3/7 Green Detection Reagent (Molecular Probes, Invitrogen), respec-
tively. 12 h before drug treatment, cells were seeded at a density of 1x104 cells (100μl) per well
in a 96-well plate. The plates were incubated with or without drugs for 24, 72, 168 hours. 10μl
of PrestoBlue and 0.2μl of Caspase-3/7 Green Detection Reagent were added to each well and
incubated for 30 minutes at 37°C. Fluorescence intensity was determined using a Varioscan
Flash plate reader (Thermo Fisher) with an excitation wavelength of 540 nm and an emission
wavelength of 590 nm, and an excitation wavelength of 502 nm and an emission wavelength of
530 nm,.
Immunohistochemistry of tissue sections
Immunohistochemical staining was performed with primary antibodies for 12h at 4°C after
blocking for 1 h at room temperature with 5% donkey serum (Millipore). Then the sections
were incubated for 1 h at room temperature with secondary antibodies (Molecular Probes).
Primary and secondary antibodies used were anti-Nestin (Abcam), anti-Olig2 (IBL), anti-
CD44 (SantaCruz), anti-Tuj1 (R&D), anti-Ki67 (Abcam), anti-GFAP (DAKO) and Alexa488
or Alexa594-conjugated donkey anti mouse or rabbit IgG (Invitrogen). The TUNEL assay was
performed using the Apoptag Fluorescein In Situ Apoptosis Detection Kit (Millipore). Slides
were analyzed with a Leica confocal laser scanning microscope (SP8, Leica).
Animal xenografts and tumor volume measurement
For in vivo experiments, CSCs (5 × 104 cells) were implanted intracranially into 10 week-old fe-
male C.B17-lcr SCID mice (Charles River). Two months after transplantation, tumor growth
was monitored by animal magnetic resonance imaging (MRI) (7.0 T horizontal-bore MR scan-
ner (Unity Inova; Agilent Technologies, Santa Clara, CA). T2-weighted magnetic resonance
imaging was performed in TR/TE 1800 /42 ms with 0.8 mm interval. The sizes of brain tumors
were measured in the images. Tumor areas were circumscribed on T2-weighted images using
ImageJ (http://imagej.nih.gov/ij/) and the total tumor volume is the sum of their corresponding
areas in cm2 multiplied by the MR interplane gap of 0.8 mm. Four days after tumor size mea-
surement, Arsenic Trioxide (2.5 mg/kg), 10058F4 (25mg/Kg) or both were administered to the
animals by i.p. injection once a day for 10days. After 10-day drug treatments, tumor sizes were
again measured using animal MRI, and they were perfused with 4% PFA, and their brains were
removed and processed for analysis. For the purpose of histological tumor volume estimation,
the brains were cut into 30μm sections and stained with hematoxylin and eosin (HE). Sections
were selected at an interval of 210μm. Tumor areas were measured using ImageJ. Tumor vol-
umes were calculated by summing the tumor areas of these sections multiplied by the cross-
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sectional interval (210μm). The institutional animal care and use committee of Shiga Medical
Center approved all of the experiments in our study (Permit number: 24–3, 25–3).
Gli reporter gene assay
GBM CSCs were transfected with a Gli luciferase reporter construct (Cignal Reporter Assay
kits) (SA Biosciences, Frederick, MD, USA) using Lipofectamine2000 (Invitrogen). The medi-
um was replaced with NeuroCult NSC Basal Medium with or without 2μM arsenic trioxide or
60μM 10058F4. After 24 hrs, cells were subjected to luciferase assay using a luminometer (Var-
ioskan Flash). Normalized luciferase activity (firefly luciferase / sea urchin luciferase ratio) was
then compared in each experiment, samples were analyzed in triplicate, and experiments were
repeated at least three times.
Results
Arsenic trioxide and 10058F4 induced differentiation of patient-derived
GBMCSCs
To confirm previous reports and examine the effects of arsenic trioxide and 10058F4, an in-
hibitor of c-Myc on the differentiation of a newly derived GBM CSC neurosphere line (RI01;
Materials and Methods), we treated dissociated neurospheres with 2μM arsenic trioxide or
60μM 10058F4 for three days in differentiating condition. Immuno-fluorescent studies
showed that 10058F4 reduced the number of Nestin-positive and Olig2-positive cells and in-
creased GFAP-positive cells (Nestin: P = 0.021, Olig2: P = 0.012, GFAP: P = 0.05 (Fig 1A and
1B). In contrast, arsenic trioxide decreased the number of GFAP-positive cells (P = 0.031) (Fig
1A and 1B). Astonishingly, 2μM arsenic trioxide as well as 10058F4 enhanced differentiation
of CSCs to TujI-positive cells (arsenic trioxide: P = 0.011, 10058F4: P = 0.024, 10058F4-arsenic
trioxide: P = 0.0036) (Fig 1A and 1B). These observations were also confirmed by western
blotting (S1A Fig). Similar results were also noted in another 3 human GBM CSC lines (RI02,
RI03 and RI08).
Arsenic trioxide enhanced inhibitory effects of 10058F4 on GBMCSC
growth
To determine whether arsenic trioxide potentiate 10058F4 effects, we treated GBM CSCs with
2μM arsenic trioxide in combination with 60μM 10058F4 in differentiating condition. Cell via-
bility assay showed that co-treatment more effectively inhibited GBM CSC cell growth than
monotherapy (RI02: F2,33 = 10.81, P = 0.0002, RI08: F2,33 = 8.02, P = .0014) (Fig 2A). In con-
trast, this cotreatment did not affect either activation of Caspase-3/7 in apoptotic signaling
(RI02: P = 0.63, RI08: P = 0.63) (Fig 2B) or the percentages of Tunel+ cells (RI02: P = 0.97,
RI08: P = 0.64) (Fig 2C), suggesting this interactive effect is not caused by enhanced apoptosis.
It has been reported that a constitutive active mutant of Notch could overcome the effect of
arsenic trioxide on GBM CSCs [18]. To examine whether Notch signaling is involved in this in-
teractive effects, we subjected GBM CSC lines to a 5x 3 doses of 10058F4 (2.4μM, 12μM,
60μM) singly and in combination with 2μM arsenic trioxide or 1μMDAPT, a Notch signaling
inhibitor. The individual and combined survival curve showed that arsenic trioxide but not
DAPT enhanced the responsiveness to 10058F4 (RI02: F1,4 = 23.20, P = 0.0085, RI08: F1,4 =
1950.419, P = 0.00001) (Fig 3). Similar results were also obtained in another 2 GBM CSC lines
(RI01, RI03).
Shh signaling is also essential for the maintenance of GBM CSCs and GBM cells often be-
come resistant to Notch inhibitor through the activation of Shh signaling [20,21]. Next, we
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examined the effects of arsenic trioxide and 10058F4 on Shh signaling in GBM CSCs. Gli re-
porter assay showed that 10058F4 activated Shh signaling in GBM CSCs but arsenic trioxide
did not enhance its effect (Fig 4). Taken together, the effect of this combination therapy seems
to be independent of Notch/ Shh signaling. However, off-target effects of these inhibitors are
not excluded in this study.
Loss of Ink4a/Arf and constitutively activated EGFR enhanced the
responsiveness to arsenic trioxide and 10058F4
EGFR activation in Ink4/Arf-deficient astrocytes and neural stem cells (NSCs) is known to pro-
voke GBM-like phenotypes[8]. A constitutively active mutant form of EGFR (EGFRvIII) trans-
forms NSCs into tumorigenic and GBM CSC-like cells. This genetically-defined system
provides an opportunity to investigate how EGFR activation with a loss of Ink4/Arf influences
the responsiveness of NSCs arsenic trioxide and 10058F4 in differentiating condition. The
Fig 1. Enhanced differentiation of cancer stem-like cells (CSCs) of glioblastomamultiforme by arsenic trioxide and 10058F4. Immunofluorescent
analysis for Nestin (green), Olig2 (red), TujI (green), GFAP(red) and DAPI staining of nuclei (blue) (A) and quantitative analysis of Nestin-positive,
Olig2-positive, Tuj1-positive, GFAP-positive cells (B) in cancer stem-like cells (CSCs) of glioblastoma multiforme (GBM) (RI01) 3days after treatment with or
without 2μM arsenic trioxide or 60μM 10058F4 in the presence of 1% FCS. Scale bar = 100μm. The data is the mean ± S.D. *P = 0.021, **P = 0.012,
***P = 0.00055, ##P = 0.024, ###P = 0.0036, §P = 0.031, §§P = 0.050.
doi:10.1371/journal.pone.0128288.g001
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Fig 2. Arsenic trioxide enhanced the inhibitory effect of 10058F4 on GBMCSC growth but not the
apoptosis-inducing effect of 10058F4.GBMCSCs (RI02, RI08) were treated with or without 2μM arsenic
trioxide or 60μM 10058F4 for 24, 72 and 168h in the presence of 1% FCS. Results are presented as the
relative cell growth (A), the activation of Caspase3/7 (B) and the percentages of Tunel+ cells (C) as
determined with PrestoBlue Cell Viability Reagent, CellEvent Caspase-3/7 Green Detection Reagent and
Tunel assay, respectively. Cell viability is presented as the mean ± SD. The relative fluorescent units of
Arsenic Trioxide Sensitizes Glioblastoma to a Myc Inhibitor
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differentiation of Ink4/Arf+/+ NSCs was not affected by 10058F4 (Fig 5A–5C). In contrast,
10058F4 caused an enhanced differentiation of retrovirally EGFRvIII-transduced Ink4/Arf-/-
NSCs to TujI-positive cells and reduced number of Nestin-positive cells (Nestin: P = 0.00001,
TujI: P = 0.0041) (Fig 5A), although arsenic trioxide enhanced TujI-positive cell differentiation
of both Ink4/Arf+/+ NSCs and EGFRvIII-transduced Ink4/Arf-/- NSCs (Ink4/Arf+/+ NSCs:
P = 0.00031, EGFRvIII-transduced Ink4/Arf-/- NSCs: P = 0.011) (Fig 5B). These results are also
confirmed by western blotting (S1B Fig). Cell viability assay showed that EGFR activation and
Ink4/Arf deficiency increased the sensitivity to co-treatment with arsenic trioxide and 10058F4
but not mono-treatment with 10058F4 (10058F4: genotype x dose interaction, F3,15 = 0.53,
P = 0.67, arsenic trioxide and 10058F4: genotype x dose interaction, F3,12 = 3.95, P = 0.036)
treated cells were normalized to the cell viability and presented as the mean ± SD. *P = 0.017, **P = 0.019,
#P = 0.72, ##P = 0.43.
doi:10.1371/journal.pone.0128288.g002
Fig 3. Arsenic trioxide but not DAPT enhanced the responsiveness of GBMCSCs to 10058F4.Dose effects of 10058F4 to GBMCSCs (RI02, RI08) in
combination with or without 2μM arsenic trioxide or 1μMDAPT for 72h. Results are presented as the relative cell growth as determined with PrestoBlue Cell
Viability Reagent. Cell viability is presented as the mean ± SD.
doi:10.1371/journal.pone.0128288.g003
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(Fig 5D). These findings raise the possibility that arsenic trioxide and 10058F4 combination
therapy might be more effective on EGFR-active Ink4/Arf-deficient GBM CSCs compared with
on normal NSCs.
Arsenic trioxide and 10058 combination treatment blocked glioma
progression in a GBM CSC xenograft model
To extend our in vitro finding, we studied the effect of arsenic trioxide and 10058F4 on in vivo
tumor growth and progression using a GBM CSC xenograft model. MRI is a promising nonin-
vasive technique to monitor treatment-induced changes in tumor growth in mice in vivo [22].
Tumor volumes derived fromMR images were well-correlated with tumor volumes estimated
by histological sections (R = 0.81, P = 0.049) (Fig 6). We assessed initial tumor growth using
MRI two months after intracranial injection of GBM CSCs, and randomized implanted mice
into arsenic trioxide, 10058F4, both or vehicle cohorts. After 10-day treatment with arsenic tri-
oxide and 10058F4, we reassessed subsequent tumor growth (Fig 7A). Arsenic trioxide and
10058F4 were well tolerated over 10-day treatment with no visible side effects (S2 Fig), which is
Fig 4. 10058F4 but not arsenic trioxide activated Shh signaling in GBMCSCs.GBMCSCs were transfected with a reporter construct containing a
response element for Gli. After 24 hour 10058F4 (60μM) and arsenic trioxide (2μM) treatment, luciferase assay was performed. Results are the mean ± S.D.
of triplicate data points from a representative experiment. *P = 0.0065 ** P = 0.0043, ***P = 0.0050, ****P = 0.0091, #P = 0.023028, ##P = 0.00015.
doi:10.1371/journal.pone.0128288.g004
Arsenic Trioxide Sensitizes Glioblastoma to a Myc Inhibitor
PLOS ONE | DOI:10.1371/journal.pone.0128288 June 3, 2015 8 / 16
Fig 5. Constitutive activation of EGFR with loss of Ink4/Arf enhanced the responsiveness of neural
stem cells to arsenic trioxide and 10058F4. (A)-(C) Immunofluorescent analysis for Nestin (green, (A)),
TujI (green (B)), GFAP (red (C)) and DAPI staining of nuclei (blue) and quantitative analysis of Nestin-positive
(A), Tuj1-positive cells (B), GFAP-positive cells (C) in Ink4/Arf-/-—EGFRvIII and control neural stem cells
3days after treatment with or without 2μM arsenic trioxide or 60μM 10058F4. Scale bar = 100μm. The data is
the mean ± S.D. *P = 0.00001, **P = 0.0041. (D) Dose effects of 10058F4 to Ink4/Arf-/-—EGFRvIII and
control neural stem cells in combination with or without 2μM arsenic trioxide for 72h. Results are presented as
Arsenic Trioxide Sensitizes Glioblastoma to a Myc Inhibitor
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consistent with previous reports [23,24]. Arsenic trioxide and 10058F4 combination treatment
but not mono-treatment regressed GBM CSC tumor (10058F4: P = 0.13, arsenic trioxide:
P = 0.95, 10058F4-arsenic trioxide: P = 0.020, one-way ANOVA, Fisher’s LSD test) (Fig 7B–7F
and S3 Fig). To determine the mechanism underlying this marked effects of arsenic trioxide
and 10058F4 co-treatment, we performed immunohistochemical analysis of treated tumor
samples. 10058F4 and cotreatment with arsenic trioxide decreased Ki67-positive proliferating
cells (10058F4: P = 0.016, 10058F4-arsenic trioxide: P = 0.0042) (Fig 8A and 8B). Arsenic triox-
ide and 10058F4 co-treated mice but not mono-treated mice exhibited drastic reduction of
Olig2-positive proneural GBM CSCs and CD44-positive mesenchymal GBM CSCs [25–27]
and enhanced differentiation to TujI-positive cells (Olig2: P = 0.027, CD44: P = 0.0075, TujI:
P = 0.00093) (Fig 8A and 8B). In addition, 10058F4 increased the number of GFAP-positive
cells (P = 0.00039), but arsenic trioxide inhibited the effect (Fig 8A and 8B). Thus these data
demonstrated that arsenic trioxide and 10058F4 co-treatment induced differentiation of GBM
CSCs in vivo with concomitant loss of GBM CSCs.
Discussion
Clinical developments of arsenic trioxide and 10058F4, a c-Myc inhibitor are limited due to
their low effectiveness, although they have important potential. 10058F4 inhibits c-Myc-
mediated transactivation in vitro, but failed to show its efficiency in vivo except for neuroblas-
toma models[24,28]. Arsenic trioxide is required to be used at higher concentrations (10–
the relative cell growth as determined with PrestoBlue Cell Viability Reagent. Cell viability is presented as the
mean ± SD.
doi:10.1371/journal.pone.0128288.g005
Fig 6. The correlation between tumor volumemeasurements fromMRI scan data and thosemade
from histological sections.GBMCSCs (RI03) CSCs (5 × 104 cells) were implanted intracranially into SCID
mice. Two months after transplantation, tumor growth was estimated by MRI and histological sections. The
correlation efficient is R = 0.81, P = 0.049.
doi:10.1371/journal.pone.0128288.g006
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Fig 7. Arsenic trioxide and 10058F4 combination treatment efficiently regressed established gliomas. Experimental Design. GBMCSCs (RI03) CSCs
(5 × 104 cells) were implanted intracranially into SCID mice. Two months after transplantation, tumor growth was monitored by MRI. Four days after tumor
size measurement, Arsenic Trioxide (2.5 mg/kg), 10058F4 (25mg/Kg) or both were administered by i.p. injection once a day for 10 days. After 10-day drug
treatments, tumor sizes were again measured. Representative images of T2-weighted MRI. The region of interest used to calculate the volume of brain tumor
is indicated by a dashed line. (C)-(D) Representative photographs of hematoxylin / eosin staining of intracranial xenograft brain tumors. The boxed area in (C)
is magnified in (D). Scale bar = 500μm. (E)-(F) Changes in tumor volume after 10-day treatment with arsenic trioxide and 10058F4 relative to the starting
tumor volume for each individual mouse. Each bar represents a volume change of an individual mouse. The data in (E) is shown as the mean ± SD of the
data for each individual mouse in (F).
doi:10.1371/journal.pone.0128288.g007
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50μM) than its safety limit for effective treatment of GBM in vivo [14–18]. Our results demon-
strated that a low concentration of arsenic trioxide (2μM) enhanced the sensitivity of GBM
CSCs to 10058F4 and that arsenic trioxide and 10058F4 combination treatment enhanced dif-
ferentiation of GBM CSCs. This preclinical efficacy of arsenic trioxide and 10058F4 combina-
tion therapy were confirmed across multiple GBMmodels: human GBM CSCs, genetically-
engineered mice GBMmodel, and human-derived GBM CSC xenografts in vivo.
Arsenic trioxide and 10058F4 have been reported to regulate metabolic pathways, which
play pivotal roles to balance quiescence and proliferation of various types of CSCs. Mainte-
nance of various stem cells including CSCs relies on anaerobic glycolysis, glutamine metabo-
lism and fatty acid metabolism for their survival and proliferation[29–31]. Stem cells and
cancer cells uptake glucose at a high rate and convert the majority of it to lactate[32]. This aero-
bic glycolysis enables an efficient supply of macromolecules for proliferation. In GBM cells,
phosphoinositol 3 kinase (PI3K)/Akt signaling and a constitutive active form of EGFR, EGFR-
vIII promote this glycolytic metabolism through c-Myc regulation [33–35]. EGFRvIII activates
Fig 8. Arsenic trioxide and 10058F4 combination treatment reduced proneural/mesenchymal GBM
CSC and induced differentiation to TujI-positive cells in a human GBMCSC xenograft model. SCID
mice were injected intracranially with 5 × 104 GBMCSCs (RI02). Treatment with arsenic Trioxide (2.5 mg/kg),
10058F4 (25mg/Kg) or both was initiated after the confirmation of tumor growth with MRI and continued daily
for 10days. Representative images from 10-day trial in a human GBMCSC xenograft model (A).
Immunofluorescent analysis for Nestin (green), Olig2 (red), CD44 (red), TujI (green), GFAP (re), Ki67 (red)
and DAPI staining of nuclei (blue) (A) and quantitative analysis of Nestin-positive, Olig2-positive,
CD44-positive, Tuj1-positive, GFAP-positive, Ki67-positive cells (B). Scale bar = 100μm. The data is the
mean ± S.D. *P = 0.05, **P = 0.001, ***P = 0.001, #P = 0.00039, §P = 0.015847, §§P = 0.0042.
doi:10.1371/journal.pone.0128288.g008
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c-Myc signaling through the control of alternative splicing of Max, a Myc binding partner, and
mTORC2-dependent upregulation of c-Myc expression level [34,35]. However, when glucose
metabolism is limited, glutaminolysis and fatty acid consumption are essential for the survival
of cancer cells [36]. Glutaminolysis is also regulated by c-Myc signaling in neuroblastoma cells
[36–38]. c-Myc coordinates the expression of the genes necessary for glutaminolysis. c-Myc di-
verts glucose-derived pyruvate into lactate from tricarboxylic acid cycle (TCA cycle) by induc-
tion of lactate dehydrogenase A (LDH-A). As a result, glucose carbon is completely away from
mitochondria, and glutamine is essential to maintain TCA cycle activity, which made c-Myc-
transformed cells susceptible to inhibition of mitochondrial electron transport chain[36,39],
which might explain cooperative effects of 10058F4 with arsenic trioxide, because arsenic triox-
ide is a mitochondrial toxin[40,41]. A c-Myc regulator, the zinc finger and X-linked transcrip-
tion factor (ZFX) is indispensable for CSC self-renewal in GBM and AML. ZFX deficiency
leads to loss of CSC properties, which can be partially rescued by overexpression of mitochon-
drial enzymes, Ptpmt1 and Idh2[42,43]. This finding also suggests the important roles of ZFX-
induced c-Myc in mitochondrial functions.
Arsenic trioxide has been shown to induce promyelocytic leukemia protein (PML) degrada-
tion[12,44]. PML promotes fatty acid oxidation through activation of peroxidase proliferator-
activated receptor (PPAR) signaling [45]. Myc can also promote fatty acid synthesis and fatty
acid oxidation [24,39,46]. Fatty acid oxidation provides acetyl-coA to maintain TCA cycle.
GBM with EGFR activation is highly dependent on fatty acid synthesis and fatty acid oxidation
for survival [47,48]. It is tempting to speculate that fatty acid synthesis and oxidation might be
another target of arsenic trioxide and 10058F4 combination therapy. PML is a member of the
tripartite motif (TRIM) family and involved in protein degradation through SUMOylation and
ubiquitination [49]. It has been reported that PML affects stabilization of c-Myc in AML cells
[50]. Another member of TRIM, TRIM3 is a tumor-suppressor of GBM [51]. This protein deg-
radation machinery might be another target of arsenic trioxide.
In summary, we demonstrated an effective pharmacological partnership between arsenic
trioxide and c-Myc inhibition that enhanced differentiation of GBM CSCs and regressed GBM
CSC tumor growth in vivo. These observations provide a foundations for further studies of ar-
senic trioxide-10058F4 combination therapy for GBM.
Supporting Information
S1 Fig. Quantification of Olig2, TujI and β-Actin in GBM CSCs and Ink4/Arf-/-—EGFRvIII
neural stem cells.Western blots showing Olig2, TujI and β-Actin levels in GBM CSCs (RI01)
(A) and Ink4/Arf-/-—EGFRvIII neural stem cells (B)1day after treatment with or without 2μM
arsenic trioxide or 60μM 10058F4.
(TIF)
S2 Fig. As2O3 and 10058F4 are well tolerated for 10-day treatment. As2O3 (2.5 mg/kg) and
10058F4 (25mg/Kg) treatment are well-tolerated for up to 10days (endpoint for this study).
Mean weight for 5 male mice over the 10-day trial. Mice were divided by treatment group: con-
trol, As2O3, 10058F4 and both. After the trial, these mice did not show any obvious
macroscopic symptoms.
(TIF)
S3 Fig. The effects of Arsenic trioxide and 10058F4 combination treatment. (A) Representa-
tive images of T2-weighted MRI. The region of interest used to calculate the volume of brain
tumor is indicated by a dashed line. GBM CSCs (RI03) CSCs (5 × 104 cells) were implanted in-
tracranially into SCID mice. Two months after transplantation, tumor growth was monitored
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by MRI. Four days after tumor size measurement, Arsenic Trioxide (2.5 mg/kg), 10058F4
(25mg/Kg) or both were administered by i.p. injection once a day for 10days. After 10-day
drug treatments, tumor sizes were again measured. (B)–(C) Representative photographs of he-
matoxylin / eosin staining of intracranial xenograft brain tumors. The boxed area in (B) is mag-
nified in (C). Scale bar = 500μm.
(TIF)
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